2026-10-14T21:41:40Z https://www.scidb.cn/oai

10.57760/sciencedb.j00217.09025 2025-08-08T11:49:31Z

2025-08-08 Advances in the study of Siglec-15 in tumors doi:10.57760/sciencedb.j00217.09025 en Siglec-15 is a newly identified target for immune normalization in recent years. It inhibits the proliferation of cytotoxic CD8+T cells and promotes the differentiation of regulatory T cells (Tregs) in tumors, thereby suppressing the tumor immune microenvironment and promoting tumor migration, invasion, and metastasis. Siglec-15, as a new target in the field of cancer immunotherapy, has tumor immune regulatory function and a different mechanism of action from PD-L1, especially in anti-PD-1/PD-L1 resistant patients with potential clinical value. This article provides an overview of the structure of Siglec-15 and its expression, mechanism of action, biological functions, prognostic value in tumors, as well as the research progress of anti-Siglec-15 antibodies in tumor treatment, aiming to explore the potential clinical value of Siglec-15 in tumor therapy, especially immunotherapy.  Siglec-15; macrophages; tumor cells; Immunosuppressive; immunotherapy; prognosis Yaru.Cao Yi.Liu Pengfei.Sun PUBLIC https://creativecommons.org/publicdomain/zero/1.0/ dataset Science Data Bank